Biomarker testing often employs IHC in many institutions, with a typical cost ranging from €22 (approximately 32 CAD) per test.25 Currently, the only available IHC antibody for clinical settings is the BRAF VE1 monoclonal antibody, which has a specificity and sensitivity of 98% and 97%, respectively, in detecting BRAF V600E mutations in melanoma.26 Despite the low cost and the short turnaround time of less than 48 hours, sole reliance on IHC alone for reflex testing is not practical since BRAF V600E mutations account for less than half of all cutaneous melanomas. The gene discussed is BRAF; the disease is cutaneous melanoma.